Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Efgartigimod in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Controlled, Retrospective, Real-Word Study

NCT06118398 is registered in ClinicalTrials.gov with Feng Jinzhou as lead sponsor.

NCT NCT06118398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06118398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Efgartigimod in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Controlled, Retrospective, Real-Word Study
Lead sponsor
Feng Jinzhou
Phase
Observational
Overall status
Unknown status
Start date
November 5, 2023
Completion date
May 5, 2025
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

efgartigimod, neuromyelitis optica